• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ACEBUTOLOL Drug Record

  • Summary
  • Interactions
  • Claims
  • ACEBUTOLOL chembl:CHEMBL642 Approved

    Alternate Names:

    C07AB04
    SECTRAL
    ACEBUTOLOL
    SECTRAL®
    3'-ACETYL-4'-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)BUTYRANILIDE
    N-(3-ACETYL-4-[2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY]PHENYL)BUTANAMIDE
    (+-)-ACEBUTOLOL
    ACETOBUTOLOL
    IL-17803A
    (±)-ACEBUTOLOL
    N-[3-ACETYL-4-[2-HYDROXY-3-[(1-METHYLETHYL)AMINO]PROPOXY]PHENYL]BUTANAMIDE
    5'-BUTYRAMIDO-2'-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)ACETOPHENONE
    ACEBUTOLOLUM
    rxcui:149
    chemidplus:37517-30-9
    drugbank:01193
    pubchem.compound:1978
    chembl:CHEMBL642

    Drug Info:

    Drug Class antihypertensive agents
    Year of Approval 1984
    FDA Approval 1984
    Drug Class small molecule
    Drug Indications Antihypertensive Agents
    (3 More Sources)

    Publications:

    Abrahamsson, 1989, Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70., Eur. J. Pharmacol.
    Fraysse et al., 2005, Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia., Environ. Toxicol. Chem.
    van den Meiracker et al., 1988, Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density., J. Cardiovasc. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Perrild et al., 1986, Short-term beta-adrenergic blockade decreases serum thyroglobulin in hyper- and euthyroid patients., J. Endocrinol. Invest.
  • ACEBUTOLOL   ADRB1

    Interaction Score: 3.72

    Interaction Types & Directionality:
    partial agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2568935 16268148 2453744 11752352 2903243


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • ACEBUTOLOL   TG

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2878948


    Sources:
    NCI

  • TdgClinicalTrial: ACEBUTOLOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antihypertensive Agents
    Drug Class small molecule
    FDA Approval 1984

    Publications:

  • TEND: ACEBUTOLOL

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval 1984
    Drug Class antihypertensive agents

    Publications:

  • DTC: ACEBUTOLOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL642 ChEMBL Drug ID

    Drug Info:

    Publications:
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem

  • NCI: ACEBUTOLOL

    • Version: 14-September-2017

    Alternate Names:
    C28806 NCI drug code

    Drug Info:

    Publications:
    Perrild et al., 1986, Short-term beta-adrenergic blockade decreases serum thyroglobulin in hyper- and euthyroid patients., J. Endocrinol. Invest.

  • TTD: Acebutolol

    • Version: 2020.06.01

    Alternate Names:
    D0HD9K TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL642

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: acebutolol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21